Rivacor

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rivacor

Quick Facts: Rivacor (Bisoprolol)

Property Description
Active Ingredient Bisoprolol fumarate
Form Film-coated tablet
Pharmacological Class Cardioselective Beta-blocker
Route of Administration Oral
Origin Synthetic (Chemically synthesized)
Type Single-ingredient product

What is the Composition and Class of Rivacor?

Rivacor is a synthetic, prescription-only medication whose active component is bisoprolol, typically supplied as the salt bisoprolol fumarate. This preparation is formulated for oral administration in the form of a film-coated tablet. It belongs to the high-level pharmacological class of beta-blockers, which are scientifically designated as adrenergic beta-antagonists. The manufacturer positioning for Rivacor emphasizes its specific use in adults requiring cardiovascular management. As a single-ingredient product, bisoprolol focuses on mediating the influence of the sympathetic nervous system on the heart. This drug is classified as a beta-blocker primarily used to help the heart work more easily.


Why is Bisoprolol Considered a Cardioselective Beta-Blocker?

Bisoprolol is designated as a cardioselective beta1-selective adrenoceptor blocking agent because its action is primarily concentrated on the beta1 receptors found predominantly in the heart. This selectivity is a defining characteristic that distinguishes it from older, non-selective beta-blockers, which affect a wider range of receptors throughout the body. The cardioselective nature of the drug ensures that its effect is mainly focused on the cardiovascular system. The compound's high affinity for beta1 receptors is a recognized pharmacological property, meaning the drug’s effects are targeted specifically toward cardiac function.


What is the General Purpose of Rivacor’s Action?

The general purpose of Rivacor is to stabilize the cardiovascular system by reducing overall cardiac workload and the stimulatory effects of adrenaline. Its primary action achieves a slowing of the heart's pace and a reduction in the force of its contractions, facilitating a stable and efficient performance. This physiological action is designed to provide stable cardiovascular support in common scenarios, such as managing long-term high blood pressure. The resulting benefit is a more consistent blood pressure and a general reduction of strain on the heart muscle over time, which is the core benefit expected from this type of antihypertensive agent.

Regulatory References

  1. National Institutes of Health (NIH) via MedlinePlus

What side effects are possible with Rivacor?

Officially Documented Adverse Reactions by Frequency

The safety profile of Rivacor (Bisoprolol) is established through official regulatory documentation, which classifies possible adverse effects based on their frequency of occurrence in clinical data. The most frequently observed event, classified as Very Common, is bradycardia (slow heart rate), which is specifically noted in patients treated for chronic heart failure.

Adverse reactions classified as Common include disorders affecting the general system and the nervous system, such as fatigue, asthenia (physical weakness), dizziness, and headache. These specific symptoms are noted in regulatory information as being more likely to occur at the beginning of the therapy. Common effects also encompass gastrointestinal disturbances, including nausea, vomiting, diarrhoea, and constipation, as well as coldness or numbness in the extremities.

Uncommon effects listed in the official label include sleep disorders and depression. A clinically significant uncommon reaction is the risk of bronchospasm (airway narrowing), particularly in individuals with a history of obstructive airways disease.

Serious Adverse Reactions and Safety Constraints

Official labeling documents address several important safety considerations. A documented serious adverse reaction is the worsening of pre-existing heart failure, a risk often noted at the start of treatment or during dosage adjustment. Furthermore, regulatory documents specify that abrupt cessation of therapy in patients with coronary artery disease may result in an exacerbation of angina pectoris or an increased risk of myocardial infarction.

Population-specific safety statements include the official caution for diabetic patients, as the medicine may mask signs of acute hypoglycemia (low blood sugar), such as a fast heartbeat. Additionally, the regulatory profile states that the safety and effectiveness have not been established for use in the pediatric population (individuals under 18 years old).

Overdose and Emergency Response

A Rivacor overdose is defined by regulator-documented clinical manifestations, primarily involving a severe reduction in cardiac function. The most common manifestations listed in official documentation are bradycardia (abnormally slow heart rate) and marked hypotension (severely low blood pressure). Overdose can also affect the Central Nervous System, presenting as confusion, dizziness, or blurred vision, or lead to acute respiratory signs such as wheezing and difficulty breathing.

Immediate medical attention is required for any suspected overdose. No specific antidote is known, and treatment is focused on providing immediate supportive and symptomatic care. Management often involves interventions like administering sympathomimetic agents to counteract effects, along with continuous monitoring of vital signs and cardiac activity (ECG). Procedures such as gastric decontamination with activated charcoal may also be necessary.

Severe or life-threatening presentations require the immediate contact of emergency services (911). These severe outcomes are explicitly listed in regulatory guidance and include collapse, seizures, profound shock, and the inability to be awakened. Furthermore, hypoglycemia (low blood sugar) is documented as a specific concern in the context of overdose for children. Hospital observation is necessary for monitoring the full course of the overdose.

Therapeutic Uses of Rivacor

Rivacor (bisoprolol) is commonly used to help with conditions that place chronic strain on the cardiovascular system. The therapeutic domains primarily involve long-term cardiac stability and blood pressure control. This medication is a core component in the sustained treatment of Chronic Heart Failure (HFrEF) and may be part of symptomatic management for patients who have suffered a heart attack. It plays a role in managing the occurrence of chronic stable angina pectorus (chest discomfort) and is essential for the long-term management of mild to moderate high blood pressure.

The therapeutic goal supports the long-term objective of managing cardiovascular risk and assists with reducing the likelihood of symptom escalation that may require clinical visits. Furthermore, it contributes to improved comfort during periods of exertion and helps maintain functional stability.

“This medication is typically applied in addressing symptoms related to heightened physiological activity and is used for conditions where symptoms may intensify temporarily.”


Quick Fact: Relief for Cardiac Strain

Area of Support Primary Benefit
Heart Failure Supports the long-term objective of managing cardiovascular risk.
Angina (Chest Pain) Plays a role in managing the occurrence of exertional chest discomfort.
Hypertension Helps maintain a sense of stability by achieving consistent blood pressure control.
Arrhythmia Is relevant for easing symptoms related to rapid or irregular heart rhythms.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Rivacor?

The official eligibility criteria for Rivacor (Bisoprolol) are strictly defined by regulatory authorities and focus on specific population groups and pre-existing conditions.

Contraindicated Populations

Use of Rivacor is absolutely prohibited (contraindicated) in patients with acute heart failure or decompensation, cardiogenic shock, severe sinus bradycardia (slow heart rate), second or third degree AV block (without a pacemaker), and severe forms of bronchial asthma or obstructive pulmonary disease. Individuals with severe peripheral arterial occlusive disease or known hypersensitivity to the active ingredient must also not use this medicine.


Age and Physiological Restrictions

Population Group Regulatory Status
Children and Adolescents (Under 18) Use not established and not recommended; safety and efficacy data are insufficient.
Adults (18 and over) Eligible Population for approved indications.
Severe Organ Impairment Restricted Use; maximum daily dose is limited (e.g., 10 mg) in severe renal or hepatic impairment.
Pregnancy Conditional Use; recommended only if the benefit clearly outweighs the potential risk to the fetus.

Patients with first degree AV block, non-severe respiratory diseases, or diabetes mellitus (with fluctuating glucose) must use Rivacor only with caution and close monitoring, as specified in regulatory documentation.

What should I know about interactions with other medicines?

Rivacor Interactions with other medicines and products

Rivacor's interaction profile is based on official government regulatory classifications, which define certain combinations as prohibited or requiring extreme caution, primarily due to additive effects on cardiac function and blood pressure.


Official Regulatory Prohibitions and Restrictions

Classification Interacting Substance/Class Regulatory Outcome
Contraindicated Floctafenine, Sultopride Prohibited co-administration due to the risk of severe cardiovascular reactions or ventricular arrhythmia.
Not Recommended Verapamil, Diltiazem (Calcium Antagonists); MAOIs (except MAO-B inhibitors); Centrally-acting Antihypertensives Increased risk of profound bradycardia, hypotension, or negative effects on atrio-ventricular conduction.

Documented Pharmacodynamic and Exposure Notes

  • Other beta-Blockers and Antiarrhythmics: Co-administration with other beta-blocking agents, Class I antiarrhythmic drugs (e.g., Quinidine), and Class III agents (e.g., Amiodarone) may potentiate effects on AV conduction time and negative inotropic action.
  • Diabetic Medications: The concurrent use of Rivacor with Insulin or Oral Anti-diabetic Drugs may increase the blood sugar lowering effect and mask the symptom of tachycardia associated with hypoglycemia.
  • Non-steroidal Anti-inflammatory Drugs (NSAIDs): NSAIDs may reduce the hypotensive effect of Rivacor, potentially limiting blood pressure control.
  • Population-Specific Exposure: Drug clearance is significantly slower in patients with severe hepatic impairment (cirrhosis) and the elimination half-life is increased approximately threefold in severe renal impairment, altering drug exposure in these populations.

Mechanism of Action

Molecular Blockade of Cardiac Sympathetic Signaling

The fundamental action of Rivacor is the competitive antagonism of the beta1-adrenergic receptors (beta1-adrenoceptors), which are the main targets for adrenaline and noradrenaline in the heart. This molecular blockade interrupts the stimulatory input from the sympathetic nervous system, thereby modifying the intracellular signaling cascade (Gs-protein/cAMP) within cardiac cells. This engagement of the beta1 receptor domain directly shapes the primary chronotropic (rate) and inotropic (force) effects of the compound.


Systemic Modulation of Vascular Regulation

The mechanism of Rivacor extends beyond the heart to influence the systemic Renin-Angiotensin System (RAS). It achieves this by blocking beta1-adrenoceptors located on juxtaglomerular cells in the kidneys, which are responsible for initiating the RAS cascade. This targeted interference results in a measurable reduction in renin secretion, which complements the cardiac effects by modifying systemic vascular resistance and cardiac output.


Mechanistic Limits and Selective Specificity

The selectivity of the mechanism is subject to concentration limits. While highly specific for the beta1 domain, this preference is dose-dependent, meaning that at elevated concentrations, the drug's binding affinity may extend to the beta2-adrenoceptors found in other tissues. This intrinsic mechanistic constraint defines the boundaries of the drug's specificity.

Dosage and Administration Information

How Rivacor is Used

Rivacor (bisoprolol fumarate) is an oral medication, typically taken as a film-coated tablet, with usage patterns strictly defined by regulatory prescribing information. The medication is designated for once-daily administration, and patients are generally instructed to take the tablet in the morning. Absorption is not significantly affected by food, so the dose may be taken with or without a meal.

Official Dosing Rules and Schedule

Indication Starting Dose Maximum Recommended Daily Dose
Hypertension / Angina Pectoris 5 mg once daily (some start at 2.5 mg) 20 mg
Chronic Heart Failure (CHF) 1.25 mg once daily 10 mg

For Chronic Heart Failure, treatment requires a defined titration phase where the initial 1.25 mg dose is gradually increased in steps (often every one to four weeks) under close clinical supervision until the target maintenance dose is reached. Tablets may be divided to achieve the required low starting doses.

Procedural Constraints

Rivacor is intended for long-term therapy. The medication must not be stopped suddenly. If treatment cessation is necessary, the dose must be gradually reduced over a period, typically 1 to 2 weeks, to prevent potential adverse effects related to abrupt withdrawal. If a dose is missed, patients should take it as soon as they remember on the same day; however, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular schedule resumed. Double doses are not permitted to compensate for a forgotten dose.

For patients with severe kidney or liver impairment, the daily dose is generally restricted, and the total dose should not exceed 10 mg.

Recent Clinical Evidence

Research evidence / Overview of studies for Rivacor

Evidence for Use in Chronic Heart Failure (Reduced Ejection Fraction)

Research for this indication has been studied through large, multinational Randomized Controlled Trials (RCTs), such as the CIBIS and CIBIS II studies, which contributed to the core body of evidence. These controlled studies was studied for adult patients with chronic, stable heart failure where the heart’s ability to pump is reduced (referred to as HFrEF). Studies was conducted during periods where patients were often receiving concurrent standard heart failure therapy.

The key outcomes measured in this research focused on outcomes related to systemic or functional imbalance, including event frequency (e.g., all-cause mortality and hospital admissions). Physiological measures such as LVEF and outcomes reflecting daily functioning or activity level (functional status) was also evaluated in these large cohorts. Studies report how symptoms evolved in the observed populations over periods often spanning 1.5 to 2 years.

Evidence for Use in High Blood Pressure (Hypertension)

Research exploring how Rivacor was studied for the condition of high blood pressure primarily consists of short-term, controlled trials and long-term observational studies. The outcomes monitored were focused on measured changes in physiological strain or stress (e.g., SBP/DBP) and Heart Rate (HR).

Studies observed responses over defined time intervals to examine the measured physiological changes. While data show patterns related to blood pressure control, information on the long-term impact on preventing major cardiovascular events in patients with uncomplicated hypertension is often grouped with research on the broader class of beta-blocker medications.


Key Research Gaps and Unanswered Questions

There are several areas where the available research is limited, and certainty remains low. One notable gap is the use of Rivacor in a specific type of heart failure known as Heart Failure with Preserved Ejection Fraction (HFpEF). Dedicated large-scale Randomized Controlled Trials for this condition are currently limited.

Furthermore, recent research has explored the question of whether continuous long-term beta-blocker therapy is necessary for patients who have had a heart attack but whose heart function remains preserved. Findings related to this area were mixed across different studies and populations, and research is ongoing to clarify the necessity of prolonged use in these patient groups. Studies help show what has been observed so far, but research provides context but not individual predictions.

Key Studies & References

  1. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
  2. Chronic heart failure in adults: diagnosis and management (NICE Guideline NG106)

Frequently Asked Questions (FAQ)

Common questions about Rivacor (FAQ)


Q: Is it necessary to have regular blood tests while taking Rivacor?

According to official documents, monitoring may be required, particularly in patients with severe kidney or liver impairment. This is because the medicine's clearance from the body is significantly slower in these conditions. Close clinical monitoring may be used by your healthcare provider, especially when the dose is first being adjusted.


Q: Does Rivacor affect liver enzyme levels?

Official regulatory reports list increased liver enzymes (such as ALT and AST) and hepatitis as rare adverse reactions. If liver function is a concern, monitoring by your healthcare provider may be considered.


Q: What is the general advice for taking Rivacor if I have diabetes?

Official documents state that this medicine should be used with caution in patients with diabetes. It may mask certain signs of low blood sugar (hypoglycemia), specifically a rapid heartbeat. However, other symptoms of low blood sugar, such as sweating, dizziness, or confusion, are generally not masked.


Q: What are the main differences between Rivacor and other similar statin drugs?

Rivacor's active ingredient, bisoprolol fumarate, is officially classified as a cardioselective beta-blocker. This is a different pharmacological class from statin drugs, which are used to manage cholesterol. Beta-blockers work by slowing the heart rate and reducing strain on the heart muscle.


Q: What happens if I accidentally take two tablets of Rivacor in one day?

Official prescribing information strictly prohibits taking a double dose to compensate for one that was missed. Symptoms of taking too much medication (overdose) can include a very slow heartbeat, severe dizziness, confusion, and blurred vision. If an overdose is suspected, official guidance recommends seeking medical assistance.


Q: Can Rivacor affect memory or cause confusion?

Confusion is not listed as a common side effect at regular doses. However, official documents list confusion as a potential symptom that may occur in cases of accidental overdose.


Q: Does Rivacor affect energy levels or cause fatigue?

Fatigue and asthenia (physical weakness) are officially listed as common adverse reactions. These symptoms are noted as being more likely to occur at the start of therapy.


Q: What are the concerns about taking Rivacor with pre-existing liver disease?

Official documents state that the drug’s clearance is significantly slower in patients with severe hepatic impairment, such as cirrhosis. This can lead to increased drug exposure. Due to this, the maximum daily dose is generally restricted in this population, as noted in the prescribing information.


Q: Is Rivacor considered a blood thinner?

Rivacor is officially classified as a cardioselective beta-blocker, or adrenergic beta-antagonist. This class of medicine is designed to manage the heart rate and blood pressure, and it is not categorized as a blood thinner (anticoagulant).


Q: Does Rivacor cause muscle pain or weakness in most patients?

Official regulatory reports list myalgia (muscle pain) as a common adverse effect, meaning it may occur in 1% to 10% of patients. Muscular weakness is listed as an uncommon adverse effect, noted in 0.1% to 1% of patients.


Q: Can Rivacor cause joint pain or body aches?

Official regulatory reporting lists arthralgia (joint pain) as a common adverse effect, which is noted to occur in 1% to 10% of patients.


Q: Does Rivacor cause changes in weight (gain or loss)?

While not listed as a common adverse event, official postmarketing reports have noted instances of weight changes. Additionally, unusual weight gain is listed as a potential symptom of overdose.


Q: Can I drink alcohol while taking Rivacor?

Official interaction notes state that alcohol may have additive effects in lowering blood pressure. This effect can potentially increase symptoms like dizziness, lightheadedness, or fainting.


Q: Are there any food restrictions I need to follow when taking Rivacor?

According to official documents, the drug's absorption is unaffected by the concomitant ingestion of food. Official information indicates the tablet may be taken with or without a meal.


Q: Do antacids like aluminum hydroxide interfere with Rivacor's absorption?

Regulatory notes suggest that antacids containing aluminum and magnesium may decrease the effectiveness of certain beta-blockers. To limit this potential interaction, the regulatory guidance notes that administration times are often recommended to be separated by at least two hours.


Q: Will Rivacor make me feel different or feel better right away?

The medicine's purpose is to achieve measurable physiological changes, such as reducing heart rate and blood pressure, which may not cause an immediate subjective feeling of improvement. However, common side effects like fatigue and dizziness are more likely to occur at the beginning of therapy.


Q: What happens to my cholesterol if I stop Rivacor suddenly?

Rivacor is officially indicated for the treatment of high blood pressure and chronic heart failure. It is not indicated for treating high cholesterol. Questions regarding the discontinuation of any medication are typically addressed by a healthcare provider.


Q: Is Rivacor safe to use while breastfeeding?

Regulatory-linked sources indicate that the drug produces low levels in milk and is generally considered acceptable during breastfeeding. However, official information notes that a healthcare provider may observe the infant for symptoms, such as unusual sleepiness or paleness.


Q: Can people with thyroid problems take Rivacor?

Official warnings state that the drug should be used with caution in patients with hyperthyroidism (an overactive thyroid). This is because it may mask some clinical signs of the condition, such as a rapid heart rate, making monitoring potentially more difficult.


Q: Are there any herbal supplements or vitamins that should be avoided when on Rivacor?

Official interaction notes specify that co-administration with a multivitamin that contains minerals may decrease the effects of the drug. For this reason, the administration times are often recommended to be separated by at least two hours in official documentation.


Q: Are there any known eye or vision-related side effects?

Official regulatory reporting lists reduced tear flow as a rare side effect, and conjunctivitis (inflammation of the eye lining) as very rare. Other visual disturbances have also been reported in clinical data.


Q: Does Rivacor work by clearing blockages or by reducing future build-up?

The drug's mechanism is described as the molecular blockade of cardiac receptors to slow the heart rate and reduce cardiac strain. The medicine is not an agent that physically clears existing blockages or plaque in the arteries.

How should Rivacor be stored and disposed of?

How to Store and Dispose of Rivacor

Official labeling mandates specific conditions to maintain the stability of Rivacor (bisoprolol) tablets. The medicine must be stored at room temperature, generally defined as below 25 C or 30 C. It is crucial to not refrigerate or freeze the tablets.

Protection and Handling

Keep the medicine in its original container, which must be kept tightly closed to protect the tablets from moisture and light. A mandatory safety rule is to keep the medicine out of the sight and reach of children.

Disposal

To discard unused or expired tablets, do not throw them away in household waste or wastewater. Disposal must follow local requirements, which often involves returning the product to a pharmacy or using an official medicine take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rivacor found in:

A-Z Index: